| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non–Small-Cell Lung Cancer: A Prospective Observational Study
|
Fukui, Tomoya
|
|
2019
|
20 |
3 |
p. 208-214.e2
|
artikel
|
| 2 |
Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133
|
Pacheco, Jose
|
|
2019
|
20 |
3 |
p. 148-160.e2
|
artikel
|
| 3 |
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol
|
Levy, Benjamin
|
|
2019
|
20 |
3 |
p. e407-e412
|
artikel
|
| 4 |
A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib
|
Zhu, You-cai
|
|
2019
|
20 |
3 |
p. e224-e228
|
artikel
|
| 5 |
A Prospective, Randomized Trial for the Comparison of 19-G and 22-G Endobronchial Ultrasound-Guided Transbronchial Aspiration Needles; Introducing a Novel End Point of Sample Weight Corrected for Blood Content
|
Wolters, Celina
|
|
2019
|
20 |
3 |
p. e265-e273
|
artikel
|
| 6 |
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer
|
Grangeon, Mathieu
|
|
2019
|
20 |
3 |
p. 201-207
|
artikel
|
| 7 |
Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer
|
Codony-Servat, Jordi
|
|
2019
|
20 |
3 |
p. 167-177
|
artikel
|
| 8 |
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI–Treated Non–Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy
|
Ding, Meijuan
|
|
2019
|
20 |
3 |
p. e229-e232
|
artikel
|
| 9 |
Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report
|
Reyes, Roxana
|
|
2019
|
20 |
3 |
p. e219-e223
|
artikel
|
| 10 |
Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-like Carcinoma: Summary of Eighty-five Cases
|
Qin, Yinyin
|
|
2019
|
20 |
3 |
p. e329-e337
|
artikel
|
| 11 |
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non–small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
|
Beau-Faller, Michèle
|
|
2019
|
20 |
3 |
p. 222-230
|
artikel
|
| 12 |
Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review
|
Li, Yalun
|
|
2019
|
20 |
3 |
p. e251-e255
|
artikel
|
| 13 |
Disparities in the Treatment and Outcome of Stage I Non–Small-Cell Lung Cancer in the 21st Century
|
Dalwadi, Shraddha M.
|
|
2019
|
20 |
3 |
p. 194-200
|
artikel
|
| 14 |
Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non–small-cell Lung Cancer
|
Wang, Buhai
|
|
2019
|
20 |
3 |
p. e233-e237
|
artikel
|
| 15 |
EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade
|
Narayanan, Anand
|
|
2019
|
20 |
3 |
p. e238-e241
|
artikel
|
| 16 |
Editorial Board
|
|
|
2019
|
20 |
3 |
p. A4
|
artikel
|
| 17 |
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer
|
Tomasini, Pascale
|
|
2019
|
20 |
3 |
p. e338-e345
|
artikel
|
| 18 |
Efficacy and Safety of Lorlatinib in Korean Non–Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor
|
Lee, Jiyun
|
|
2019
|
20 |
3 |
p. 215-221
|
artikel
|
| 19 |
EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non–small cell Lung Cancer Treated With Erlotinib
|
Winther-Larsen, Anne
|
|
2019
|
20 |
3 |
p. 161-166.e1
|
artikel
|
| 20 |
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial
|
Vernieri, Claudio
|
|
2019
|
20 |
3 |
p. e413-e417
|
artikel
|
| 21 |
Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma
|
Ahn, Sung Soo
|
|
2019
|
20 |
3 |
p. e299-e308
|
artikel
|
| 22 |
Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma
|
Sukrithan, Vineeth
|
|
2019
|
20 |
3 |
p. e242-e246
|
artikel
|
| 23 |
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non–small-cell Lung Cancer (NSCLC): A Report of 2 Cases
|
Schwarz, Michael
|
|
2019
|
20 |
3 |
p. e247-e250
|
artikel
|
| 24 |
Immunotherapy for LELC: Case Report and a Focused Review
|
Darrason, Marie
|
|
2019
|
20 |
3 |
p. e393-e401
|
artikel
|
| 25 |
Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non–small-cell Lung Cancer
|
Nakamura, Masaki
|
|
2019
|
20 |
3 |
p. e256-e264
|
artikel
|
| 26 |
Increased Galectin-1 Expression in Thymic Epithelial Tumors
|
Riess, Jonathan W.
|
|
2019
|
20 |
3 |
p. e356-e361
|
artikel
|
| 27 |
Inoperable Pulmonary Carcinoid Tumors: Local Control Rates With Stereotactic Body Radiotherapy/Hypofractionated RT With Image-Guided Radiotherapy
|
Singh, Deepinder
|
|
2019
|
20 |
3 |
p. e284-e290
|
artikel
|
| 28 |
Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non–small-cell Lung Carcinoma and Brain Metastases
|
Wei, Yu-Feng
|
|
2019
|
20 |
3 |
p. e274-e283
|
artikel
|
| 29 |
MET Immunohistochemistry Should Be Avoided in Selecting Non–small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis
|
Lambros, Laetitia
|
|
2019
|
20 |
3 |
p. e418-e420
|
artikel
|
| 30 |
Palliative Care Referrals for Advanced Non–small-cell Lung Cancer (NSCLC): Patient and Provider Attitudes and Practices
|
Feld, Emily
|
|
2019
|
20 |
3 |
p. e291-e298
|
artikel
|
| 31 |
Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids
|
Naraev, Boris G.
|
|
2019
|
20 |
3 |
p. e376-e392
|
artikel
|
| 32 |
Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non–Small-Cell Lung Cancer
|
Park, Wungki
|
|
2019
|
20 |
3 |
p. 143-147
|
artikel
|
| 33 |
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
|
Wheatley-Price, Paul
|
|
2019
|
20 |
3 |
p. e362-e368
|
artikel
|
| 34 |
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non–Small-Cell Lung Cancer
|
Nokihara, Hiroshi
|
|
2019
|
20 |
3 |
p. e317-e328
|
artikel
|
| 35 |
Predictors of Nodal and Metastatic Failure in Early Stage Non–small-cell Lung Cancer After Stereotactic Body Radiation Therapy
|
Cerra-Franco, Alberto
|
|
2019
|
20 |
3 |
p. 186-193.e3
|
artikel
|
| 36 |
Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter Study
|
Janssens, Annelies
|
|
2019
|
20 |
3 |
p. e369-e375
|
artikel
|
| 37 |
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)
|
Hiranuma, Osamu
|
|
2019
|
20 |
3 |
p. e402-e406
|
artikel
|
| 38 |
Role of Skip Mediastinal Lymph Node Metastasis for Patients With Resectable Non–small-cell Lung Cancer: A Propensity Score Matching Analysis
|
Wang, Lin
|
|
2019
|
20 |
3 |
p. e346-e355
|
artikel
|
| 39 |
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression
|
Ricciuti, Biagio
|
|
2019
|
20 |
3 |
p. 178-185.e2
|
artikel
|
| 40 |
Table of Contents
|
|
|
2019
|
20 |
3 |
p. A5-A8, A15-A16
|
artikel
|
| 41 |
Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients
|
Nam, Bo Da
|
|
2019
|
20 |
3 |
p. e309-e316
|
artikel
|
Tijdschrift beschrijving